This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2) (Malbec)

This study has been terminated.
(Low recruitment in spite of strategies implemented)
Information provided by:
Sanofi Identifier:
First received: February 22, 2008
Last updated: June 1, 2010
Last verified: June 2010

To compare in terms of HbA1c insulin naive patients with Type 2 Diabetes starting with insulin glargine on an algorithm with insulin naive patients starting with insulin glargine on the physician's standard practice.

To compare in terms of FBG insulin naïve patients starting with insulin glargine on an algorithm with insulin naïve patients starting with insulin glargine on the physician's standard practice.

To compare the percentage of patients achieving HbA1c< 7% in each treatment group.

To compare hypoglycaemic events (minor, severe and nocturnal) between groups.

To compare average insulin dose between groups.

To compare PRO (patients' reported outcomes) between groups.

To compare mean changes in body weight between treatment groups.

Condition Intervention Phase
Type 2 Diabetes Drug: Insulin Glargine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 24 Weeks, Randomized, 2 Arms, Controlled, Multi-centre, National, Open-labeled, Parallel Study in Insulin naïve Patients With Type 2 Diabetes to Compare a Lantus Titration Algorithm vs. Physician's Standard Practice

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Mean difference in HbA1c (efficacy) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Minor, severe and nocturnal Hypoglycaemic events (safety) [ Time Frame: from the begining of the treatment up to 5 days after the end of the study ]

Enrollment: 9
Study Start Date: January 2008
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
Drug: Insulin Glargine

In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.

For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.

Active Comparator: B
This is the control group, following the physician's standard practice.
Drug: Insulin Glargine
For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.


Ages Eligible for Study:   21 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with type 2 diabetes.
  • Patients in treatment with OADs (one or more) for at least 1 year who failed metabolic control (HbA1c > 8% and < 11%).
  • FBG > 130 mg/dl and < 240 mg/dl.
  • BMI < 40 kg/m2 and >25 kg/m2.
  • Ability and willingness to follow a tight anti-diabetic therapy and to perform SMBG controls.

Exclusion Criteria:

  • C peptide < 0.30 nmol/l.
  • Unexplained weight loss of more than 10% of body weight in the last 6 months.
  • Pregnant women or women with the intention of becoming pregnant.
  • Women with childbearing potential who will not use contraceptive protection.
  • Breastfeeding women.
  • Patients using or that have used rapid or ultra-rapid acting insulins; except for those patients that have used rapid or ultra-rapid insulins during intercurrences such as AMI, severe infection or surgery.
  • Renal impairment defined as serum creatinine >1.4 mg/dl in women and >1.5 mg/dl in men.
  • Hepatic impairment defined as GPT or GOT above 2x the normal threshold.
  • Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (non selective beta blockers and systemic corticosteroids).
  • History of drug or alcoholic abuse.
  • Diabetic retinopathy with surgical treatment in the 3 months prior to study entry or which may require surgical treatment within 6 months of study entry.
  • Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological, endocrine, hematological, oncologic or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, at the discretion of the investigator.
  • Evidence of an uncooperative attitude, including poor compliance to any anti- diabetic treatment.
  • Known hypersensitivity to insulin glargine.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00627471

Sanofi-aventis administrative office Argentina
Buenos Aires, Argentina
Sponsors and Collaborators
Study Director: Cristian von Schulz-Hausmann Sanofi-aventis administrative office Argentina
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00627471     History of Changes
Other Study ID Numbers: LANTU_L_02936
Study First Received: February 22, 2008
Last Updated: June 1, 2010

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on July 24, 2017